Trial Profile
A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 14 Apr 2021 Status changed from active, no longer recruiting to completed.
- 17 Nov 2020 Planned End Date changed from 15 Mar 2021 to 12 Mar 2021.
- 06 Oct 2020 Planned End Date changed from 16 Apr 2021 to 15 Mar 2021.